Receptor Systems & Pharmacology

Allosteric modulators bind to sites distinct from the orthosteric (primary ligand) binding site. Positive allosteric modulators (PAMs) enhance the affinity or efficacy of the natural ligand without activating the receptor independently. Negative allosteric modulators (NAMs) reduce the natural ligand's effect. This approach offers advantages over direct agonism or antagonism: it preserves the temporal pattern of endogenous signalling (enhancing or dampening rather than replacing), may offer greater receptor subtype selectivity (allosteric sites are less conserved than orthosteric sites), and avoids complete receptor blockade. Allosteric modulation is an emerging strategy in peptide receptor pharmacology.

AUC is calculated by integrating the plasma concentration-time curve from time zero to either a specific time point (AUC0-t) or infinity (AUC0-∞, extrapolated). AUC represents total systemic drug exposure and is directly proportional to the amount of drug absorbed (bioavailable dose). AUC is the primary parameter for bioequivalence assessment — two formulations are bioequivalent if their AUC and Cmax values fall within 80-125% of each other. For peptide drugs, AUC comparisons between formulations (e.g. oral vs injectable semaglutide) help establish dose equivalence. AUC also appears in the fundamental PK equation: CL = F × Dose / AUC.

Absolute bioavailability (F) is calculated as AUC(non-IV route)/AUC(IV) × 100%. Factors affecting peptide bioavailability: Oral: destruction by gastric acid and GI proteases, poor epithelial permeability, and first-pass metabolism yield F typically <1-2%. Oral semaglutide with SNAC achieves F ~0.4-1% — enough for efficacy at the 14mg daily dose because the GLP-1R requires very low concentrations. Subcutaneous: F is 60-90%, limited by incomplete absorption from the injection site and local degradation. Intramuscular: F is similar to SC but absorption may be faster. Nasal: F is 1-10% for peptides, limited by the nasal epithelial barrier and mucociliary clearance. Bioavailability directly determines the relationship between administered dose and drug exposure.

Bradykinin is a 9 amino acid peptide cleaved from high-molecular-weight kininogen by the enzyme kallikrein during activation of the contact (kinin-kallikrein) system. It acts on two receptors: B1 (induced during inflammation) and B2 (constitutively expressed). B2 receptor activation causes vasodilation, increased vascular permeability, pain, and smooth muscle contraction. In hereditary angioedema, C1-esterase inhibitor deficiency leads to uncontrolled bradykinin production and severe swelling. Icatibant is a synthetic decapeptide (10 amino acids) that contains five non-natural amino acids, making it a potent competitive B2 receptor antagonist resistant to proteolytic degradation, with a half-life of approximately 1-2 hours.

Clearance (CL) reflects the body's overall ability to eliminate a drug: CL = Dose/AUC. For small peptides (<5 kDa), renal filtration is the dominant clearance mechanism, with glomerular filtration rates of approximately 120 mL/min. Larger peptides and albumin-bound peptides are cleared more slowly because they are not efficiently filtered. Proteolytic degradation by tissue and plasma enzymes contributes to clearance at all molecular weights. Unlike small molecule drugs, peptides are generally not metabolised by hepatic CYP450 enzymes, which means peptide drugs have a lower propensity for metabolic drug-drug interactions. Clearance determines maintenance dose requirements: Dose rate at steady state = CL × target Css.

cAMP is synthesised from ATP by adenylyl cyclase (activated by Gαs-coupled GPCRs) and degraded by phosphodiesterases (PDEs). The GLP-1 receptor signals primarily through cAMP/PKA: GLP-1R activation → Gαs → adenylyl cyclase → cAMP → PKA → CREB phosphorylation → insulin gene transcription; cAMP also activates Epac2, which contributes to insulin granule exocytosis. The GHRH receptor also signals through cAMP to stimulate GH gene transcription and secretion. Somatostatin receptors couple to Gαi, which inhibits adenylyl cyclase and reduces cAMP, explaining somatostatin's inhibitory effects. The cAMP/PKA pathway is thus a convergence point for both stimulatory and inhibitory peptide hormone signalling.

Desensitisation occurs in two phases: homologous desensitisation (specific to the activated receptor, mediated by G-protein coupled receptor kinases/GRKs and beta-arrestins) and heterologous desensitisation (affecting multiple receptor types, mediated by protein kinase A/C). GRKs phosphorylate the agonist-occupied receptor, promoting beta-arrestin binding, which sterically blocks G-protein coupling and targets the receptor for internalisation via clathrin-coated pits. For GnRH agonists, both desensitisation and subsequent downregulation contribute to the therapeutic suppression of gonadotropin release. The rate and degree of desensitisation vary by receptor type and cell type.

DPP-4 (CD26) is a serine protease expressed on cell surfaces (particularly in the endothelium, kidney, liver, and immune cells) and circulating as a soluble form in plasma. It cleaves a dipeptide from the N-terminus of peptides with alanine or proline at position 2 — GLP-1(7-36) is cleaved to inactive GLP-1(9-36) and GIP(1-42) to inactive GIP(3-42). This cleavage occurs within 1-2 minutes of secretion. Two therapeutic strategies address DPP-4: oral DPP-4 inhibitors (sitagliptin, saxagliptin — small molecules that block the enzyme, extending endogenous GLP-1/GIP activity) and injectable GLP-1 receptor agonists (structurally modified to resist DPP-4 cleavage entirely). GLP-1 RAs produce much larger pharmacological effects because they achieve supraphysiological receptor activation.

Dose titration is used when the dose-response curves for efficacy and side effects differ in their threshold doses. For GLP-1 RAs, gastrointestinal side effects (nausea, vomiting) are most prominent at treatment initiation, while efficacy accumulates over weeks. Starting low and escalating allows the GI tract to adapt (tachyphylaxis to nausea) before reaching fully effective doses. Semaglutide (Ozempic) titration: 0.25mg weekly × 4 weeks → 0.5mg × 4 weeks → 1mg (target for diabetes); for weight management (Wegovy): continued escalation to 2.4mg. Tirzepatide titrates from 2.5mg to 5/10/15mg. Dose titration schedules are established during Phase II dose-ranging trials and refined in Phase III.

Dose-response curves are typically sigmoidal (S-shaped) when plotted on a semi-logarithmic scale. Key parameters include: ED50 (median effective dose), EC50 (median effective concentration), Emax (maximum effect), and Hill coefficient (curve steepness). For GLP-1 RAs, gastrointestinal side effects show a steeper dose-response curve at initial exposure than at steady state (explaining why titration reduces side effects), while weight loss and HbA1c reduction show dose-dependent improvements across the therapeutic range. Some peptides show bell-shaped dose-response curves (hormesis) where higher doses produce diminished effects due to receptor desensitisation or activation of opposing pathways.

Receptor downregulation involves multiple processes: agonist-induced receptor internalisation via clathrin-coated pits and endosomes, increased lysosomal degradation of internalised receptors, and decreased receptor gene transcription. The time course of downregulation (hours to days) is slower than desensitisation (minutes). In GnRH agonist therapy, continuous exposure causes GnRH receptor downregulation from approximately 15,000-20,000 receptors per gonadotroph cell to much lower levels over 1-2 weeks. This reduces pituitary responsiveness to GnRH, suppressing LH/FSH secretion and downstream sex steroid production. The degree and reversibility of downregulation depends on agonist concentration, exposure duration, and receptor reserve.

Tirzepatide is a single peptide that activates GLP-1R with approximately 5-fold lower potency than native GLP-1 and GIPR with approximately equal potency to native GIP. The SURPASS clinical trial programme demonstrated superior HbA1c reduction and the SURMOUNT programme demonstrated superior weight loss compared to selective GLP-1 RAs. The dual mechanism produces complementary effects — GLP-1R activation provides glucose-dependent insulin secretion, appetite suppression, and delayed gastric emptying, while GIPR activation may contribute additional metabolic and central appetite effects. The success of dual agonism has catalysed development of triple agonists (GLP-1R/GIPR/glucagon receptor) as next-generation metabolic therapies.

Pharmacological efficacy (intrinsic efficacy) reflects the quality of the receptor-drug interaction — specifically, the conformational change induced in the receptor and the magnitude of downstream signalling. A full agonist induces the optimal conformational change for maximum signalling (efficacy = 1). A partial agonist induces a suboptimal change (efficacy 0-1). An antagonist binds without inducing productive signalling (efficacy = 0). This receptor-level concept is distinct from clinical efficacy (how well a drug treats a disease in patients). A partial agonist with lower pharmacological efficacy may still be clinically effective if partial receptor activation is sufficient for the therapeutic goal.

Elimination half-life reflects the terminal phase of drug decline in the body. For peptides with multi-compartmental pharmacokinetics (common for larger peptides and those with tissue binding), there may be an initial rapid distribution phase followed by a slower elimination phase. The elimination half-life is the clinically relevant parameter for determining dosing intervals. At steady state (reached after approximately 4-5 half-lives of regular dosing), the amount of drug eliminated between doses equals the amount administered. For semaglutide with a ~1 week elimination half-life, steady state is reached after approximately 4-5 weeks of weekly dosing.

When an oral drug is absorbed from the GI tract, it enters the portal venous system and passes through the liver before reaching systemic circulation. The liver's metabolic enzymes (CYP450 family for small molecules, proteases for peptides) and the gut wall's enzymes can extensively degrade the drug during this first pass. For oral peptides, first-pass destruction is compounded by pre-absorptive degradation in the GI lumen (by pepsin, trypsin, chymotrypsin) and poor epithelial permeability. The combined effect yields oral bioavailability typically <1% for peptides. Oral semaglutide's SNAC formulation partially addresses GI degradation but not hepatic first-pass, which is why the oral dose (14mg) is much higher than the SC dose (1mg for equivalent glycaemic effect).

GPCRs are the largest superfamily of membrane receptors, with approximately 800 members in the human genome. They share a common architecture: seven transmembrane alpha-helices connected by three extracellular and three intracellular loops. Peptide hormones typically bind to the extracellular domain and/or transmembrane pocket. Upon agonist binding, the receptor undergoes a conformational change that exposes the intracellular surface to G-proteins, catalysing GDP-to-GTP exchange on the Gα subunit and initiating downstream signalling. GPCRs are targeted by approximately 34% of all FDA-approved drugs. Peptide-binding GPCRs include Class A (rhodopsin-like: opioid, somatostatin, chemokine receptors) and Class B (secretin-like: GLP-1R, GIPR, GHRHR, GLP-2R, calcitonin-R, PTH-R).

Tesamorelin (Egrifta) is trans-3-hexenoic acid-GHRH(1-44)-NH2 — the full-length GHRH sequence with a hexenoic acid modification at the N-terminus that improves stability. It is administered as a daily subcutaneous injection. Research GHRH analogues include CJC-1295 with DAC (Drug Affinity Complex, a lysine-reactive linker that covalently binds albumin for sustained release), CJC-1295 without DAC (identical to Modified GRF 1-29 — a GHRH(1-29) analogue with substitutions at positions 2, 8, 15, 27), and sermorelin (GHRH(1-29)-NH2 without stabilising substitutions, previously approved but discontinued). The research variants differ primarily in half-life extension strategy and duration of GH stimulation.

GIP (glucose-dependent insulinotropic polypeptide) acts through the GIPR, a GPCR expressed on pancreatic beta cells, adipocytes, osteoblasts, and brain neurons. Tirzepatide activates both GLP-1R and GIPR — its GIP component may contribute to superior weight loss through central appetite mechanisms and peripheral metabolic effects. Interestingly, both GIP receptor agonism and antagonism have shown metabolic benefits in preclinical models, creating debate about the optimal approach. Several investigational compounds targeting GIP receptors (alone or in combination with GLP-1R and glucagon receptors) are in clinical development, representing a highly active area of metabolic drug research.

GLP-1 receptor agonists bind to GLP-1 receptors on pancreatic beta cells (stimulating glucose-dependent insulin secretion), alpha cells (suppressing glucagon), brain regions (reducing appetite), and gastrointestinal smooth muscle (slowing gastric emptying). The approved agents differ in structure and dosing: exenatide (Byetta, twice-daily; Bydureon, weekly) is based on exendin-4 from Gila monster venom; liraglutide (Victoza/Saxenda, daily) and semaglutide (Ozempic/Wegovy, weekly; Rybelsus, daily oral) are human GLP-1 analogues with fatty acid modifications; dulaglutide (Trulicity, weekly) is fused to an Fc fragment; lixisenatide (Adlyxin, daily) is exendin-based; tirzepatide (Mounjaro/Zepbound, weekly) is a dual GLP-1/GIP agonist. The class has demonstrated cardiovascular benefits beyond glucose control.

GnRH agonists exploit the pulsatility-dependence of the GnRH receptor. Natural GnRH is released in pulses (approximately every 60-90 minutes) — this pulsatile pattern is essential for maintaining normal LH and FSH secretion. Continuous GnRH exposure (from depot or implant formulations) initially stimulates gonadotropin release (flare phase, 1-2 weeks), then causes receptor desensitisation, downregulation (reduced receptor number), and uncoupling from intracellular signalling pathways. The net result is profound suppression of LH, FSH, and downstream sex steroids (testosterone, oestrogen) to castrate or postmenopausal levels. This paradoxical use of agonists to achieve suppression is the pharmacological basis for treating hormone-sensitive prostate cancer, endometriosis, precocious puberty, and for pituitary suppression in fertility protocols.

GnRH antagonists competitively occupy GnRH receptors on pituitary gonadotrophs, immediately blocking endogenous GnRH binding. This produces rapid, dose-dependent suppression of LH, FSH, and sex steroids without the initial flare seen with agonists. Injectable antagonists (cetrorelix, ganirelix — used in IVF; degarelix — used in prostate cancer) are peptides with modifications to resist degradation. Oral antagonists (relugolix for prostate cancer/fibroids; elagolix for endometriosis) are non-peptide small molecules designed from the GnRH receptor pharmacophore. The choice between agonist and antagonist depends on whether the flare phase is clinically acceptable — antagonists are preferred when immediate suppression is needed.

GHS are classified by mechanism: GHRH receptor agonists (tesamorelin, CJC-1295/Mod GRF 1-29) stimulate GH release via the GHRH pathway on pituitary somatotrophs, while ghrelin receptor (GHS-R1a) agonists (GHRP-2, GHRP-6, ipamorelin, hexarelin, MK-677/ibutamoren) mimic ghrelin's action through a distinct pathway. The two pathways are synergistic — combining GHRH and ghrelin receptor stimulation produces greater GH release than either alone. Tesamorelin is the only approved GHS. Research GHS are widely discussed in online peptide communities, though their long-term safety profiles in humans are not established through adequate clinical trials. Some GHRPs also affect cortisol, prolactin, and appetite (notably GHRP-6 increases hunger).

GHRH is a 44 amino acid peptide (GHRH(1-44)-NH2) released from arcuate and ventromedial nuclei of the hypothalamus in a pulsatile pattern. It travels via the hypothalamic-hypophyseal portal system to the anterior pituitary, binding GHRH receptors (a GPCR) on somatotroph cells. Receptor activation increases intracellular cAMP, stimulating both GH gene transcription and GH vesicle secretion. Natural GHRH has a half-life of approximately 7 minutes due to rapid cleavage by DPP-4 (at position 2) and other plasma proteases. The biologically active fragment is GHRH(1-29), and Modified GRF(1-29) is a research analogue with amino acid substitutions at positions 2, 8, 15, and 27 to resist DPP-4 and improve stability.

Half-life (t1/2) is related to clearance (CL) and volume of distribution (Vd) by the equation: t1/2 = 0.693 × Vd/CL. Native GLP-1: t1/2 ≈ 1-2 min (rapid DPP-4 cleavage). Exenatide: t1/2 ≈ 2.4 hours (DPP-4 resistant exendin-4 backbone, twice-daily dosing). Liraglutide: t1/2 ≈ 13 hours (C-16 albumin binding, daily dosing). Semaglutide SC: t1/2 ≈ 165 hours ≈ 1 week (C-18 albumin binding + Aib, weekly dosing). Half-life extension strategies for peptides include: albumin binding (lipidation), PEGylation (increased size), Fc fusion (FcRn recycling — used by dulaglutide and romiplostim), depot formulations (microspheres, implants), and amino acid modifications (DPP-4 resistance, protease resistance). Achieving the desired half-life is a primary goal of peptide drug design.

The incretin effect was discovered when researchers observed that oral glucose produced 2-3 times greater insulin secretion than the same glucose load given intravenously (the incretin effect accounts for approximately 50-70% of post-meal insulin response). GLP-1 (from L-cells) and GIP (from K-cells) are the two identified incretins. Both are rapidly degraded by DPP-4 — GLP-1 has a half-life of 1-2 minutes, GIP approximately 5-7 minutes. In type 2 diabetes, the incretin effect is diminished: GIP's insulinotropic action is impaired (though GIP secretion may be normal or increased), while GLP-1's action is largely preserved but secretion may be reduced. This differential impairment partly explains why GLP-1 receptor agonists are more effective than DPP-4 inhibitors for glucose lowering.

The incretin effect is quantified by comparing insulin secretion during oral versus intravenous glucose administration at matched glycaemic levels (isoglycaemic clamp). The difference represents incretin-mediated insulin release. In healthy individuals, 50-70% of insulin secreted after an oral glucose load is attributable to incretins. In type 2 diabetes, this proportion is reduced to approximately 20-30% (the impaired incretin effect). This impairment results from both reduced GLP-1 secretion and pancreatic beta cell resistance to GIP. GLP-1 receptor agonists bypass the impaired incretin effect by providing supraphysiological GLP-1R activation, achieving insulin secretory responses that native incretin release cannot.

Intrinsic activity (α) was defined by Ariens as the proportional maximum response: α = 1 for full agonists, 0 < α < 1 for partial agonists, α = 0 for antagonists. The concept was later refined by Stephenson's efficacy theory, which separated receptor occupancy from stimulus production. In modern pharmacology, intrinsic efficacy (Furchgott's concept) accounts for receptor reserve — tissues with many spare receptors can achieve maximum response at submaximal receptor occupancy, meaning even partial agonists may produce full responses in receptor-rich tissues. These concepts are relevant to understanding why peptide drugs may produce different responses in different tissues expressing the same receptor.

Some receptors exhibit constitutive activity — they produce a low-level biological signal even without ligand binding. A neutral antagonist blocks additional activation but leaves constitutive activity intact. An inverse agonist actively suppresses constitutive activity below baseline. The distinction between antagonism and inverse agonism is pharmacologically significant because inverse agonists can produce effects even in the absence of the natural ligand. Many compounds previously classified as antagonists have been reclassified as inverse agonists upon closer investigation. While more commonly discussed for small molecule GPCRs, the concept applies to any constitutively active receptor system.

KOR activation in the periphery produces analgesia and antipruritic (anti-itch) effects. In the CNS, KOR activation produces dysphoria (opposite of euphoria) and sedation — which is why CNS-penetrant KOR agonists have poor tolerability. Difelikefalin was deliberately designed as a peripherally restricted KOR agonist, with physicochemical properties (high polarity, low lipophilicity, D-amino acid incorporation) preventing BBB penetration. It achieves therapeutic antipruritic effects in CKD patients on haemodialysis by activating peripheral KOR without central side effects. This design strategy demonstrates how understanding receptor distribution and BBB pharmacology enables targeted peptide drug design.

Loading dose = target Css × Vd / F, where Css is the desired steady-state concentration, Vd is volume of distribution, and F is bioavailability. Loading doses are useful when the half-life is long enough that reaching steady state through maintenance dosing alone would take an unacceptably long time (remember: steady state requires ~4-5 half-lives). For a drug with a 1-week half-life, steady state takes ~4-5 weeks with regular dosing. Loading doses are more commonly used for small molecule drugs (e.g. amiodarone) and some antibiotics. For GLP-1 RAs, the dose titration approach (starting low, escalating gradually) serves a different purpose than loading — it's about tolerability, not speed to steady state.

Maintenance dose = CL × Css / F (where CL is clearance, Css is target steady-state concentration, F is bioavailability). At steady state, the amount eliminated between doses equals the maintenance dose administered. For peptide drugs, maintenance doses are established through dose-ranging trials that identify the dose producing optimal benefit-risk balance. The maintenance dose of semaglutide for type 2 diabetes is 0.5 or 1.0mg weekly (Ozempic), while the weight management maintenance dose is 2.4mg weekly (Wegovy). Some patients may require dose adjustment based on tolerability — not all patients can tolerate the full maintenance dose, and dose reduction may be needed for those with persistent side effects.

Peptide drug mechanisms include: receptor agonism (GLP-1 RAs stimulate insulin release via GLP-1R; GnRH agonists initially stimulate then downregulate GnRH-R), receptor antagonism (GnRH antagonists block GnRH-R; icatibant blocks bradykinin B2R), enzyme inhibition (bortezomib inhibits the 20S proteasome; ACE inhibitors block angiotensin-converting enzyme), hormone replacement (somatropin replaces deficient GH; desmopressin replaces deficient vasopressin), antimicrobial membrane disruption (daptomycin, colistin disrupt bacterial membranes; vancomycin inhibits cell wall synthesis), and complement inhibition (zilucoplan blocks C5 cleavage). The mechanism of action determines the drug's effects, side effects, contraindications, and potential drug interactions.

The five MCRs have distinct tissue distributions and functions: MC1R (melanocytes → pigmentation; afamelanotide is an agonist), MC2R (adrenal cortex → cortisol production via ACTH; corticotropin and cosyntropin act here), MC3R (brain → energy homeostasis; bremelanotide activates MC3R and MC4R), MC4R (hypothalamus → appetite and energy balance; setmelanotide is a selective MC4R agonist for genetic obesity), MC5R (sebaceous glands and other tissues → sebum production). The endogenous ligands are melanocortins derived from proopiomelanocortin (POMC): α-MSH, β-MSH, γ-MSH, and ACTH. Agouti-related peptide (AgRP) is an endogenous MC3R/MC4R antagonist. MC4R loss-of-function mutations cause monogenic obesity — the specific target of setmelanotide.

MOR is the primary target of classical opioid analgesics (morphine, oxycodone, fentanyl) and endogenous beta-endorphin. MOR activation in the brain produces potent analgesia, euphoria, and reward — these effects underlie both therapeutic utility and abuse potential. MOR activation also causes respiratory depression (the primary cause of opioid overdose death), constipation, and physical dependence. The development of peptide drugs that selectively avoid MOR activation (such as difelikefalin's KOR selectivity) or that target opioid pathways peripherally represents an important strategy for providing pain relief and related therapeutic effects without opioid-class adverse effects.

In the GH axis: GH stimulates hepatic IGF-1 production; IGF-1 feeds back to suppress hypothalamic GHRH and pituitary GH release. Exogenous GH (somatropin) suppresses endogenous GH through this loop. In the HPG axis: testosterone/oestrogen feed back to suppress hypothalamic GnRH and pituitary LH/FSH. GnRH agonist-induced testosterone suppression removes this feedback, which is why LH initially rises (flare) before receptor downregulation takes effect. In the HPA axis: cortisol feeds back to suppress hypothalamic CRH and pituitary ACTH. Understanding feedback loop dynamics is essential for predicting both therapeutic effects and potential complications of peptide hormone therapies.

Opioid receptors (mu/MOR, delta/DOR, kappa/KOR, and the related nociceptin/orphanin FQ receptor/NOP) are GPCRs found throughout the nervous system and periphery. Mu receptors mediate analgesia, euphoria, respiratory depression, and physical dependence — the effects of morphine and fentanyl. Delta receptors modulate pain and mood. Kappa receptors mediate analgesia, dysphoria, and antipruritic effects. Difelikefalin is a highly selective KOR agonist (>500-fold selectivity over MOR) designed to not cross the blood-brain barrier, providing peripheral antipruritic and analgesic effects without central euphoria, addiction potential, or respiratory depression. This peripherally restricted approach represents a significant pharmacological advancement.

Partial agonists have lower intrinsic efficacy than full agonists — they cannot produce the maximum possible receptor response even when all receptors are occupied. In the presence of a full agonist, a partial agonist competes for receptor binding while producing a weaker signal, effectively reducing overall response (functional antagonism). This dual agonist/antagonist behaviour can be therapeutically useful when moderate, controlled receptor activation is desired. The concept of partial agonism is quantified by the intrinsic activity (alpha value) — full agonists have alpha = 1, partial agonists have 0 < alpha < 1, and antagonists have alpha = 0.

Cmax depends on the dose, rate of absorption, and rate of elimination. For SC peptide injections, Cmax typically occurs 1-8 hours after injection (Tmax). For oral peptides, Cmax depends on gastric emptying and absorption kinetics. For IV bolus, Cmax occurs immediately. Cmax is clinically relevant because side effects often correlate with peak concentrations — the nausea associated with GLP-1 RAs may be partly related to Cmax. Extended-release formulations and albumin-binding strategies blunt Cmax (producing flatter pharmacokinetic profiles), which can improve tolerability. Cmax and AUC together define the drug's exposure profile and are both required for bioequivalence determinations.

PD describes the concentration-effect relationship using key concepts: potency (EC50 — concentration producing 50% maximum effect), efficacy (Emax — maximum achievable effect), Hill coefficient (steepness of the concentration-response curve), and receptor occupancy theory (fraction of receptors occupied at a given drug concentration). For GLP-1 RAs, PD effects include insulin secretion (EC50 varies by compound), glucagon suppression, gastric emptying delay, and appetite reduction — each with potentially different concentration-response relationships. PK/PD modelling integrates pharmacokinetic data (how concentrations change over time) with pharmacodynamic data (how effects relate to concentrations) to optimise dosing regimens and predict clinical outcomes.

PK properties are described by the ADME framework. Absorption: subcutaneous bioavailability is typically 60-90%, oral peptide bioavailability is usually <1-2% (oral semaglutide ~0.4-1%). Distribution: most peptides distribute primarily in extracellular fluid with small Vd (0.1-0.3 L/kg); albumin-bound peptides have distribution limited by albumin's distribution. Metabolism: unlike small molecules metabolised by hepatic CYP450 enzymes, peptides are degraded by ubiquitous tissue and plasma proteases, reducing drug interaction risk. Excretion: peptide fragments are filtered by kidneys; intact larger peptides and albumin-bound peptides are filtered less efficiently. Key PK parameters include Cmax, Tmax, AUC, half-life (t1/2), clearance (CL), and volume of distribution (Vd).

Potency is measured by the EC50 (concentration producing 50% maximum response in a functional assay) or the ED50 (dose producing 50% maximum response in vivo). A drug with an EC50 of 1 nM is 10-fold more potent than one with an EC50 of 10 nM. Potency determines the dose required — more potent drugs can achieve effects at lower doses. However, potency alone does not indicate clinical superiority; efficacy (maximum achievable response), selectivity, pharmacokinetic properties, and safety all contribute. Among GLP-1 RAs, semaglutide is more potent at the GLP-1 receptor than liraglutide, contributing to its ability to achieve clinical effects at lower molar doses.

Agonists produce effects by binding to the same site as the natural ligand (orthosteric agonists) or at a different site that enhances receptor activity (allosteric agonists). The degree of activation varies: full agonists produce maximal receptor response, while partial agonists produce submaximal response even at full receptor occupancy. In peptide therapeutics, GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, tirzepatide) are the most commercially significant class. Other examples include GnRH agonists (goserelin, leuprolide), melanocortin agonists (bremelanotide, setmelanotide, afamelanotide), GHRH agonists (tesamorelin), and vasopressin/oxytocin receptor agonists.

Competitive antagonists bind reversibly to the same receptor site as the natural ligand, with their effect depending on the relative concentrations of agonist and antagonist. Non-competitive antagonists bind irreversibly or at allosteric sites, reducing maximal receptor response regardless of agonist concentration. In peptide therapeutics, GnRH antagonists (cetrorelix, ganirelix, degarelix, relugolix, elagolix) provide immediate gonadotropin suppression without flare. Icatibant competitively antagonises bradykinin B2 receptors. The choice between agonist and antagonist strategies depends on the target biology — GnRH agonists exploit downregulation while antagonists exploit direct blockade.

Binding affinity is quantified by the dissociation constant (Kd) — the ligand concentration at which 50% of receptors are occupied at equilibrium. Lower Kd = higher affinity. Affinity is determined by association rate (kon — how quickly the ligand binds) and dissociation rate (koff — how quickly it releases). For therapeutic peptides, high affinity generally correlates with potency but not always with efficacy. Very high affinity can sometimes lead to prolonged receptor activation causing desensitisation. Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) are standard techniques for measuring peptide-receptor binding kinetics. Binding affinity data are a key component of preclinical pharmacological characterisation.

The kidneys filter blood through approximately 1 million glomeruli, each with a molecular weight cutoff of approximately 60-70 kDa. Peptides below this threshold are freely filtered unless bound to larger carriers. Unbound peptide fragments are extensively filtered and reabsorbed/degraded by proximal tubular cells. Strategies to reduce renal clearance: PEGylation (adds 5-40 kDa mass), albumin binding (albumin ~67 kDa is not filtered + FcRn recycling extends its t1/2 to ~19 days), and Fc fusion (IgG Fc ~25 kDa per chain + FcRn recycling). Renal impairment can reduce peptide clearance and increase drug exposure, potentially requiring dose adjustment — this is assessed in dedicated renal impairment pharmacokinetic studies.

The major second messenger systems are: cAMP pathway (Gαs-activated adenylyl cyclase → cAMP → PKA), cGMP pathway (receptor or soluble guanylyl cyclase → cGMP → PKG — relevant to natriuretic peptides and linaclotide), IP3/DAG pathway (Gαq-activated PLC → IP3 + DAG → calcium release + PKC), and calcium signalling (calcium as a universal intracellular messenger). Second messengers amplify the initial receptor signal — a single receptor activation can produce thousands of second messenger molecules, which in turn activate many downstream enzymes. This amplification cascade explains how picomolar concentrations of peptide hormones can produce large physiological effects.

Selectivity is quantified as the ratio of binding affinities or functional potencies at the target receptor versus off-target receptors. Difelikefalin has >500-fold selectivity for KOR over MOR (Ki ratio). Setmelanotide is approximately 20-fold selective for MC4R over MC3R. Highly selective peptides tend to have cleaner side effect profiles. Selectivity can be engineered through amino acid substitutions, conformational constraint, and systematic structure-activity relationship studies. For receptor families with closely related subtypes (like the 5 melanocortin receptors or 5 somatostatin receptors), achieving selectivity is a significant design challenge — pasireotide's broader SSTR binding profile compared to octreotide illustrates how different selectivity profiles lead to different clinical applications.

Most peptide hormone receptors are GPCRs, which activate heterotrimeric G-proteins (Gαs, Gαi, Gαq subtypes). Gαs-coupled receptors (GLP-1R, GHRHR) activate adenylyl cyclase, increasing intracellular cAMP, which activates protein kinase A (PKA). Gαq-coupled receptors activate phospholipase C, generating IP3 (calcium release) and DAG (protein kinase C activation). Gαi-coupled receptors inhibit adenylyl cyclase, decreasing cAMP. Beyond G-protein signalling, GPCRs also signal through beta-arrestin pathways (biased agonism), which can produce different downstream effects than G-protein signalling. The concept of biased agonism — where a ligand preferentially activates one signalling pathway over another — is an emerging strategy in peptide drug design.

Natural somatostatin (SRIF-14 and SRIF-28) acts on five receptor subtypes (SSTR1-5). Its half-life of 1-3 minutes makes it therapeutically impractical. Synthetic analogues are truncated and stabilised: octreotide (8 aa, cyclic) and lanreotide (8 aa, cyclic) are selective for SSTR2 and SSTR5 — the subtypes most relevant to GH-secreting and NET tumour cells. Pasireotide (6 aa, cyclic) binds SSTR1, 2, 3, and 5, with particular affinity for SSTR5, which is highly expressed on corticotroph adenomas (Cushing's disease). Long-acting formulations include octreotide LAR (PLGA microspheres, monthly IM), lanreotide autogel (self-assembling nanotubes, monthly deep SC), and pasireotide LAR (microspheres, monthly IM).

At steady state, plasma concentrations fluctuate between Cmax (peak after each dose) and Ctrough (just before the next dose) around a mean steady-state concentration (Css). For drugs with short half-lives relative to the dosing interval, these fluctuations are large. For drugs with long half-lives (like weekly semaglutide), fluctuations are minimal, providing relatively constant drug exposure. Time to reach steady state depends only on half-life (approximately 4-5 × t1/2), not on dose. Loading doses can achieve near-steady-state concentrations immediately. Dose titration schedules for GLP-1 RAs ensure that steady-state concentrations are reached gradually at each dose level, allowing adaptation to side effects.

Tachyphylaxis occurs rapidly (minutes to hours) upon repeated or continuous exposure, distinguishing it from the slower development of tolerance (days to weeks). Mechanisms include receptor phosphorylation, beta-arrestin recruitment (which uncouples the receptor from G-protein signalling), and depletion of downstream signalling intermediates. In peptide therapeutics, the GnRH agonist mechanism exploits tachyphylaxis — continuous GnRH receptor stimulation leads to rapid desensitisation and subsequent downregulation. For some peptide drugs, tachyphylaxis to side effects (like nausea with GLP-1 RAs) is beneficial, while tachyphylaxis to therapeutic effects would be problematic. Understanding tachyphylaxis potential guides dosing interval design.

The therapeutic window is bounded by the minimum effective concentration (MEC, below which the drug lacks clinical benefit) and the minimum toxic concentration (MTC, above which unacceptable adverse effects occur). A wide therapeutic window (large MTC/MEC ratio) indicates greater dosing flexibility and safety margin. Peptide drugs generally have wide therapeutic windows due to their receptor specificity, though the window may differ by endpoint — for GLP-1 RAs, the therapeutic window for weight management may not be identical to that for glycaemic control. Drugs with narrow therapeutic windows (such as vancomycin) require therapeutic drug monitoring to maintain concentrations within the optimal range.

Tolerance develops through multiple mechanisms: receptor downregulation (reduced receptor number), receptor desensitisation (reduced receptor sensitivity), enhanced drug metabolism (metabolic/pharmacokinetic tolerance), and physiological counter-regulation (homeostatic mechanisms opposing the drug's effect). For peptide drugs, some degree of tolerance to gastrointestinal side effects of GLP-1 RAs is observed (nausea typically diminishes over weeks), which is beneficial. However, significant tolerance to the primary therapeutic effect (glycaemic control, weight loss) has not been a major issue for GLP-1 RAs at currently approved doses. Cross-tolerance (tolerance to related drugs that share the same mechanism) is an important consideration when switching between agents in the same class.

Triple agonists targeting GLP-1, GIP, and glucagon receptors simultaneously aim to leverage the glucagon receptor's effects on energy expenditure, hepatic lipid metabolism, and appetite suppression alongside the established benefits of GLP-1 and GIP receptor activation. Retatrutide (LY3437943) is the most advanced triple agonist in clinical development, with Phase II results showing mean weight loss of approximately 24% at 48 weeks — surpassing tirzepatide's results. The glucagon component is hypothesised to increase energy expenditure and promote hepatic fat reduction, potentially benefiting NASH as well as obesity. Balancing the three receptor activities to maximise efficacy while managing safety is a key design challenge.

Ctrough (Cmin) is measured by collecting a blood sample immediately before the next scheduled dose. For drugs where efficacy requires maintaining concentrations above a minimum threshold (like antibiotics), Ctrough monitoring ensures adequate coverage. For peptide drugs with long half-lives (semaglutide: Ctrough is approximately 80% of Cmax due to the long t1/2 and flat PK profile), trough fluctuation is minimal. For shorter-acting peptides, the Ctrough-to-Cmax ratio may be much lower, and clinical effects may wane before the next dose. Vancomycin trough monitoring (target 15-20 mg/L for serious infections) is the most common example of trough-based therapeutic drug monitoring for a peptide drug.

Upregulation involves increased receptor gene transcription, enhanced mRNA stability, increased receptor protein synthesis, and/or decreased receptor internalisation and degradation. Clinically, upregulation creates the risk of supersensitivity when a chronically administered antagonist is discontinued — the upregulated receptors become suddenly available to endogenous agonists, potentially producing an exaggerated response (rebound phenomenon). For peptide drugs, understanding upregulation dynamics is important for managing drug discontinuation, dose tapering strategies, and predicting rebound effects.

Vd is a theoretical volume — it equals the amount of drug in the body divided by the plasma concentration. A Vd close to plasma volume (~3L) indicates the drug remains mainly in blood. A Vd close to extracellular fluid volume (~14L) indicates distribution into interstitial fluid. Very large Vd (>total body water ~42L) indicates extensive tissue binding. Most peptides have small Vd (0.05-0.3 L/kg) because their size and hydrophilicity restrict distribution. Albumin-bound peptides have Vd approximately equal to albumin's Vd (~0.1 L/kg). The combination of small Vd and moderate-to-low clearance contributes to the long half-lives of albumin-bound peptide drugs.